If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEkf Diagnostics Regulatory News (EKF)

Share Price Information for Ekf Diagnostics (EKF)

Share Price is delayed by 15 minutes
Get Live Data
26.30    0.00 (0.00%)
Bid:
25.60
Ask:
26.20
Spread: 0.60 (2.344%)
Market Cap: £113.16m
EKF Live PriceLast checked at - London Stock Exchange

Intraday Ekf Diagnostics Share Chart

Executive Chair share purchase

16 Dec 2025 07:00

RNS Number : 6381L
EKF Diagnostics Holdings PLC
16 December 2025
 

EKF Diagnostics Holdings plc

("EKF" or the "Company")

 

Executive Chair share purchase

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, announces that on Monday 15 December, Julain Baines, Executive Chair, purchased a total of 85,000 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at a price of 23.0 pence per Ordinary Share.

 

Following this transaction, Julian Baines' total interest in the Company is 1,751,288 Ordinary Shares, representing approximately 0.40% of the total voting rights over the Company's issued share capital.

 

The Notification of Dealing Form required in accordance with UK MAR is set out below as is the Standard form for notification of major holdings received by EKF today.

 

EKF Diagnostics Holdings plc

www.ekfdiagnostics.com

Julian Baines, Executive Chair

 Via Walbrook PR

Gavin Jones, Chief Executive Officer

 

Tel: +44 (0)20 7496 3000

Singer Capital Markets (Nominated Adviser & Broker)

 

Phil Davies / Oliver Platts

Walbrook PR Limited

Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com

Paul McManus / Alice Woodings

Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

 

EKF is an AIM-listed global diagnostics business focussed on:

 

· Point-of-Care analysers in the key areas of Hematology and Diabetes.

· Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic food and industrial applications.

 

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.

 

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

 Julian Baines

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Executive Chair

b)

 

Initial notification /Amendment

 

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

EKF Diagnostics Holdings plc

b)

 

LEI

 

 

213800DXTF3EAUK1AR05

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of 1 pence each

Identification code

GB0031509804

 

b)

 

Nature of the transaction

 

 

Purchase of Ordinary Shares

c)

 

Price(s) and volume(s)

Price(s)

Volume(s)

23p

85,000

d)

 

Aggregated information

- Aggregated volume

N/A single transaction

- Price

e)

 

Date of the transaction

 

 

 15 December 2025

f)

 

Place of the transaction

 

 

London Stock Exchange, AIMX

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHUVVVRVOUUAAA
Date   Source Headline
18th Jun 201310:17 amRNSDirector Share Transfer
11th Jun 20133:52 pmRNSAmendment to Long-Term Incentive Plan
15th May 20134:34 pmRNSResult of AGM
15th May 20137:00 amRNSAGM Statement
13th May 20137:00 amRNSFirst PointMan DNA enrichment products launched
15th Apr 20131:34 pmRNSPublication of Annual Report & Notice of AGM
18th Mar 20137:00 amRNSFinal Results
4th Mar 20137:00 amRNSEstablishment of EKF Molecular & Acquisition
18th Jan 20137:00 amRNSPre-close Trading Update
21st Dec 20123:53 pmRNSDirectors' Exercise of Options
17th Dec 20127:00 amRNSHolding(s) in Company
27th Nov 20124:32 pmRNSHolding(s) in Company
9th Nov 20127:00 amRNSIssue of Equity
24th Sep 20127:00 amRNSHalf Yearly Report
5th Sep 20127:00 amRNSTrading Update
14th Aug 20127:00 amRNSNICE guidance on type 2 diabetes
10th Aug 20127:00 amRNSHemoCue settlement agreement
17th Jul 20127:00 amRNSLicensing agreement for kidney markers
16th Jul 20123:05 pmRNSHolding(s) in Company
16th Jul 20127:00 amRNSQuo-Lab CE marking & Commercial launch
12th Jul 20121:11 pmRNSHolding(s) in Company
28th Jun 20127:00 amRNSDirector's Share Options
26th Jun 201210:30 amRNSHolding(s) in Company
23rd May 20121:00 pmRNSResult of AGM
11th May 20127:00 amRNSUpdate on Disposal of IBL AG
20th Apr 201211:18 amRNSPublication of Annual Report & Notice of AGM
18th Apr 20124:50 pmRNSHolding(s) in Company
5th Apr 20127:00 amRNSDirectors' Exercise of Options
5th Apr 20127:00 amRNSChina Patent Grant
3rd Apr 20121:47 pmRNSHolding(s) in Company
27th Mar 20127:00 amRNSDisposal of International Brand Licensing AG
26th Mar 20128:18 amRNSAdviser Change of Name
21st Mar 20127:00 amRNSFinal Results
20th Mar 20127:00 amRNSAppointment of Group Head of Sales
16th Mar 20127:00 amRNSTrading Update & Notice of Final Results
8th Mar 20127:00 amRNSUS Patent Grant
6th Feb 20127:00 amRNSNew US contract win
30th Jan 20122:08 pmRNSHolding(s) in Company
19th Jan 20127:00 amRNSPre-Close Trading Update
30th Nov 20117:00 amRNSContract win
29th Nov 20117:00 amRNSUpdate on US market expansion
24th Oct 20115:53 pmRNSHolding(s) in Company
24th Oct 20115:51 pmRNSHolding(s) in Company
12th Oct 201112:42 pmRNSHolding(s) in Company
7th Oct 20113:44 pmRNSHolding(s) in Company
29th Sep 20115:14 pmRNSHolding(s) in Company
28th Sep 20117:01 amRNSDirectorate Change
28th Sep 20117:00 amRNSHalf Yearly Report
27th Sep 20117:00 amRNSChange of Adviser
23rd Sep 20111:26 pmRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.